Transvenous Lead Removal Post-Market Clinical Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03688412 |
|
Recruitment Status :
Completed
First Posted : September 28, 2018
Last Update Posted : May 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Cardiac Electrophysiology | Device: Cook lead extraction devices |
| Study Type : | Observational |
| Actual Enrollment : | 230 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | RELEASE: Transvenous Lead Removal Using the Cook Evolution® Lead Extraction System Post-Market Clinical Study. |
| Actual Study Start Date : | October 18, 2018 |
| Actual Primary Completion Date : | January 28, 2020 |
| Actual Study Completion Date : | May 11, 2020 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Cook lead extraction devices
The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
|
Device: Cook lead extraction devices
The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects. |
- Rate of complete procedural success [ Time Frame: Immediately following lead extraction ]Complete procedural success is the removal of the targeted lead and all lead material from the vascular space, with the absence of permanently disabling complications or procedure-related death.
- Rate of clinical procedural success [ Time Frame: Immediately following lead extraction ]Clinical procedural success is the removal of all targeted leads and all lead material from the vascular space, or retention of a small portion of the lead (fragment that is 4 cm or smaller) that does not negatively impact the outcome goals of the procedure.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients must be 18 years of age or older
- Lead indwell time greater than 1 year
Exclusion Criteria:
- Patient is unable or unwilling to provide informed consent (per the IRB/EC requirements) to participate in the clinical study
- Patient presents with an extracardiac lead
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03688412
| United States, California | |
| UCSF Medical Center | |
| San Francisco, California, United States, 94143 | |
| United States, Illinois | |
| Carle Foundation | |
| Urbana, Illinois, United States, 61801 | |
| United States, North Carolina | |
| NC Heart and Vascular Reseach | |
| Raleigh, North Carolina, United States, 27607 | |
| United States, Pennsylvania | |
| Wellspan York Hospital | |
| York, Pennsylvania, United States, 17403 | |
| United States, Texas | |
| Memorial Hermann | |
| Houston, Texas, United States, 77030 | |
| United States, Virginia | |
| University of VA Medical Center | |
| Charlottesville, Virginia, United States, 22908 | |
| Germany | |
| German Heart Center Berlin | |
| Berlin, Germany | |
| Netherlands | |
| Isala | |
| Zwolle, Netherlands | |
| United Kingdom | |
| St. George's University Hospital | |
| London, United Kingdom, SW17 0QT | |
| Responsible Party: | Cook Research Incorporated |
| ClinicalTrials.gov Identifier: | NCT03688412 |
| Other Study ID Numbers: |
16-04 |
| First Posted: | September 28, 2018 Key Record Dates |
| Last Update Posted: | May 28, 2020 |
| Last Verified: | May 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | Cook Research Incorporated (CRI) is fully committed to supporting the principles of responsible data sharing, including providing qualified scientific researchers access to deidentified, patient-level data from CRI clinical studies to conduct legitimate scientific research. Data underlying the results reported in this clinical study will be made available for request after publication of the results from this study and ending 5 years after initial publication. Interested researchers may review the "Cook Research Incorporated Policy on Access to Clinical Study Data" at https://www.cookresearchinc.com/extranet/data-access.html and submit a complete research proposal to request data access. Additional study documents (such as the study protocol) will be shared as needed if the data access request is granted. A data sharing agreement will be executed for access to deidentified patient-level data. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Cardiac pacing, artificial Cardiac Resynchronizaton Therapy Devices Defibrillators, Implantable |

